EP2917244 - APROTININ-DERIVED POLYPEPTIDE-ANTIBODY CONJUGATES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 12.11.2021 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 04.12.2020 | ||
Former | Grant of patent is intended Status updated on 28.05.2020 | ||
Former | Examination is in progress Status updated on 18.01.2019 | Most recent event Tooltip | 27.04.2024 | Lapse of the patent in a contracting state New state(s): MK | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states Angiochem Inc. 201 President Kennedy Avenue Suite PK-2880 Montréal, QC H2X 3Y7 / CA | [2015/40] |
Former [2015/38] | For all designated states Angiochem Inc. 201 President Kennedy Avenue Suite PK-R220 Montréal, QC H2X 3Y7 / CA | Inventor(s) | 01 /
TRIPATHY, Sasmita 4451 King Street Pierrefonds Québec H9H 2G2 / CA | 02 /
DEMEULE, Michel 343 Preston Drive Beaconsfield Québec H9W 1Z2 / CA | 03 /
CURRIE, Jean-Christophe 2 Rue Lord Repentigny Québec J6A 6C9 / CA | [2015/38] | Representative(s) | Lahrtz, Fritz, et al Patentanwälte Isenbruck Bösl Hörschler PartG mbB Seckenheimer Landstr. 4 68163 Mannheim / DE | [2021/01] |
Former [2015/38] | Lahrtz, Fritz Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68 81675 München / DE | Application number, filing date | 13853308.8 | 12.11.2013 | [2015/38] | WO2013CA50863 | Priority number, date | US201261725365P | 12.11.2012 Original published format: US 201261725365 P | [2015/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014071531 | Date: | 15.05.2014 | Language: | EN | [2014/20] | Type: | A1 Application with search report | No.: | EP2917244 | Date: | 16.09.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 15.05.2014 takes the place of the publication of the European patent application. | [2015/38] | Type: | B1 Patent specification | No.: | EP2917244 | Date: | 06.01.2021 | Language: | EN | [2021/01] | Search report(s) | International search report - published on: | CA | 15.05.2014 | (Supplementary) European search report - dispatched on: | EP | 16.06.2016 | Classification | IPC: | C07K19/00, A61K47/68, A61P35/00, A61P35/04, C07K14/81, C07K16/28 | [2020/25] | CPC: |
A61K38/57 (EP,US);
A61K47/6811 (EP,US);
A61K47/6843 (EP,US);
A61K47/6849 (EP,US);
A61K47/6855 (EP,US);
A61K47/6889 (EP,US);
A61P25/00 (EP);
A61P35/00 (EP);
A61P35/04 (EP);
|
Former IPC [2015/38] | C07K19/00, A61K47/48, A61P35/00, A61P35/04, C07K14/81, C07K16/28 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/38] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | AUS APROTININ GEWONNENE ANTIKÖRPERKONJUGATE | [2015/38] | English: | APROTININ-DERIVED POLYPEPTIDE-ANTIBODY CONJUGATES | [2015/38] | French: | CONJUGUÉS POLYPEPTIDE DÉRIVÉ D'APROTININE-ANTICORPS | [2015/38] | Entry into regional phase | 28.05.2015 | National basic fee paid | 28.05.2015 | Search fee paid | 28.05.2015 | Designation fee(s) paid | 28.05.2015 | Examination fee paid | Examination procedure | 28.05.2015 | Examination requested [2015/38] | 11.01.2017 | Amendment by applicant (claims and/or description) | 22.01.2019 | Despatch of a communication from the examining division (Time limit: M06) | 31.07.2019 | Reply to a communication from the examining division | 29.05.2020 | Communication of intention to grant the patent | 07.10.2020 | Fee for grant paid | 07.10.2020 | Fee for publishing/printing paid | 07.10.2020 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 22.01.2019 | Opposition(s) | 07.10.2021 | No opposition filed within time limit [2021/50] | Fees paid | Renewal fee | 30.11.2015 | Renewal fee patent year 03 | 28.11.2016 | Renewal fee patent year 04 | 27.11.2017 | Renewal fee patent year 05 | 27.11.2018 | Renewal fee patent year 06 | 27.11.2019 | Renewal fee patent year 07 | 27.11.2020 | Renewal fee patent year 08 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 12.11.2013 | AL | 06.01.2021 | AT | 06.01.2021 | CY | 06.01.2021 | CZ | 06.01.2021 | EE | 06.01.2021 | FI | 06.01.2021 | HR | 06.01.2021 | LT | 06.01.2021 | LV | 06.01.2021 | MC | 06.01.2021 | MK | 06.01.2021 | PL | 06.01.2021 | RO | 06.01.2021 | RS | 06.01.2021 | SI | 06.01.2021 | SK | 06.01.2021 | SM | 06.01.2021 | BG | 06.04.2021 | NO | 06.04.2021 | GR | 07.04.2021 | IS | 06.05.2021 | PT | 06.05.2021 | [2024/22] |
Former [2023/30] | HU | 12.11.2013 | |
AL | 06.01.2021 | ||
AT | 06.01.2021 | ||
CY | 06.01.2021 | ||
CZ | 06.01.2021 | ||
EE | 06.01.2021 | ||
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
MC | 06.01.2021 | ||
PL | 06.01.2021 | ||
RO | 06.01.2021 | ||
RS | 06.01.2021 | ||
SI | 06.01.2021 | ||
SK | 06.01.2021 | ||
SM | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
IS | 06.05.2021 | ||
PT | 06.05.2021 | ||
Former [2023/27] | HU | 12.11.2013 | |
AL | 06.01.2021 | ||
AT | 06.01.2021 | ||
CZ | 06.01.2021 | ||
EE | 06.01.2021 | ||
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
MC | 06.01.2021 | ||
PL | 06.01.2021 | ||
RO | 06.01.2021 | ||
RS | 06.01.2021 | ||
SI | 06.01.2021 | ||
SK | 06.01.2021 | ||
SM | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
IS | 06.05.2021 | ||
PT | 06.05.2021 | ||
Former [2022/33] | AL | 06.01.2021 | |
AT | 06.01.2021 | ||
CZ | 06.01.2021 | ||
EE | 06.01.2021 | ||
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
MC | 06.01.2021 | ||
PL | 06.01.2021 | ||
RO | 06.01.2021 | ||
RS | 06.01.2021 | ||
SI | 06.01.2021 | ||
SK | 06.01.2021 | ||
SM | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
IS | 06.05.2021 | ||
PT | 06.05.2021 | ||
Former [2022/23] | AL | 06.01.2021 | |
AT | 06.01.2021 | ||
CZ | 06.01.2021 | ||
EE | 06.01.2021 | ||
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
PL | 06.01.2021 | ||
RO | 06.01.2021 | ||
RS | 06.01.2021 | ||
SI | 06.01.2021 | ||
SK | 06.01.2021 | ||
SM | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
IS | 06.05.2021 | ||
PT | 06.05.2021 | ||
Former [2022/13] | AL | 06.01.2021 | |
AT | 06.01.2021 | ||
CZ | 06.01.2021 | ||
EE | 06.01.2021 | ||
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
PL | 06.01.2021 | ||
RO | 06.01.2021 | ||
RS | 06.01.2021 | ||
SI | 06.01.2021 | ||
SK | 06.01.2021 | ||
SM | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
PT | 06.05.2021 | ||
Former [2022/10] | AL | 06.01.2021 | |
AT | 06.01.2021 | ||
CZ | 06.01.2021 | ||
EE | 06.01.2021 | ||
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
PL | 06.01.2021 | ||
RO | 06.01.2021 | ||
RS | 06.01.2021 | ||
SK | 06.01.2021 | ||
SM | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
PT | 06.05.2021 | ||
Former [2022/07] | AL | 06.01.2021 | |
AT | 06.01.2021 | ||
CZ | 06.01.2021 | ||
EE | 06.01.2021 | ||
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
PL | 06.01.2021 | ||
RO | 06.01.2021 | ||
RS | 06.01.2021 | ||
SK | 06.01.2021 | ||
SM | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
IS | 06.05.2021 | ||
PT | 06.05.2021 | ||
Former [2021/50] | AT | 06.01.2021 | |
CZ | 06.01.2021 | ||
EE | 06.01.2021 | ||
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
PL | 06.01.2021 | ||
RO | 06.01.2021 | ||
RS | 06.01.2021 | ||
SK | 06.01.2021 | ||
SM | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
IS | 06.05.2021 | ||
PT | 06.05.2021 | ||
Former [2021/48] | AT | 06.01.2021 | |
CZ | 06.01.2021 | ||
EE | 06.01.2021 | ||
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
PL | 06.01.2021 | ||
RS | 06.01.2021 | ||
SM | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
IS | 06.05.2021 | ||
PT | 06.05.2021 | ||
Former [2021/46] | AT | 06.01.2021 | |
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
PL | 06.01.2021 | ||
RS | 06.01.2021 | ||
SM | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
IS | 06.05.2021 | ||
PT | 06.05.2021 | ||
Former [2021/42] | AT | 06.01.2021 | |
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
PL | 06.01.2021 | ||
RS | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
IS | 06.05.2021 | ||
PT | 06.05.2021 | ||
Former [2021/39] | AT | 06.01.2021 | |
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
PL | 06.01.2021 | ||
RS | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
PT | 06.05.2021 | ||
Former [2021/37] | AT | 06.01.2021 | |
FI | 06.01.2021 | ||
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
LV | 06.01.2021 | ||
RS | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
PT | 06.05.2021 | ||
Former [2021/36] | FI | 06.01.2021 | |
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
BG | 06.04.2021 | ||
NO | 06.04.2021 | ||
GR | 07.04.2021 | ||
PT | 06.05.2021 | ||
Former [2021/35] | FI | 06.01.2021 | |
HR | 06.01.2021 | ||
LT | 06.01.2021 | ||
NO | 06.04.2021 | ||
PT | 06.05.2021 | ||
Former [2021/33] | FI | 06.01.2021 | |
LT | 06.01.2021 | ||
NO | 06.04.2021 | ||
PT | 06.05.2021 | Documents cited: | Search | [I]WO2007009229 (ANGIOCHEM INC [CA], et al) [I] 1-15 * page 9, line 31 - page 10, line 1; table 2 *; | [I]WO2008144919 (ANGIOCHEM INC [CA], et al) [I] 1-15 * page 45, line 7 - page 46, line 12; figures 1-7; tables 1,2; sequences 97,107 * * page 50, line 12 - page 54, line 2; figure 16; examples 4,11,12; claim - *; | [I]US2009016959 (BELIVEAU RICHARD [CA], et al) [I] 1-15 * example -; claims 12,13; table 2 *; | [I]WO2012000118 (ANGIOCHEM INC [CA], et al) [I] 1-15 * page 68 - page 70; example -; claims 63,69; tables 2,4,5; sequence 97 *; | [IP]US2013280281 (CASTAIGNE JEAN-PAUL [CA], et al) [IP] 1-15* example -; table - *; | [I] - ]!AN E LACHOWICZ ET AL, "Design of new Angiopep-2-anti-EGFR and Angiopep-2-anti-Her2 derivatives with increased blood-brain barrier permeability for treatment of brain tumors", NEURO-ONCOLOGY : OFFICIAL JOURNAL OF THE WORLD FEDERATION OF NEURO-ONCOLOGY, OXFORD : OXFORD UNIV. PRESS, GB, (20120115), vol. 14, no. Suplement, ISSN 1523-5866, pages VI30 - VI31, XP008178859 [I] 1-15 *see abstract number ET-29* | International search | [X]WO2010121379 (ANGIOCHEM INC [CA], et al); | [X]WO2011060206 (U3 PHARMA GMBH [DE], et al); | [X] - LACHOWICZ, J.E. ET AL., "Design of new Angiopep-2-anti-EGFR and Angiopep-2-anti-Her2 derivatives with increased blood-brain barrier permeability for treatment of brain tumors", NEURO-ONCOLCOLOGY., WASHINGTON, D.C., (20121015), vol. 14, no. SUPPL, pages VI25 - VI37, XP008178859 | [XP] - LACHOWICZ, J.E. ET AL., "ANG4043: A new brain-penetrant peptide-antibody conjugate that reduces tumor growth in a HER2-positive orthotopic tumor model. [abstract].", PROCEEDINGS OF THE 104TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, WASHINGTON, DC. PHILADELPHIA (PA), (20130415), vol. 73, no. 8, XP008178860 |